Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients

A prospective, crossover study

Yalcin Solak, Zeynep Biyik, Huseyin Atalay, Abduzhappar Gaipov, Figen Guney, Suleyman Turk, Adrian Covic, David Goldsmith, Mehmet Kanbay

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Aim: Pruritus is common in dialysis patients. Peripheral neuropathy is also prevalent in this patient population. However, the role of neuropathy in the genesis of uraemic itch has not been adequately studied to date. Therefore, we aimed to investigate the effects of gabapentin and pregabalin on uraemic pruritus along with neuropathic pain in patients receiving haemodialysis. Methods: This is a 14 week long randomized, prospective, cross-over trial. Haemodialysis patients with established neuropathy and/or neuropathic pain were included. Fifty patients were randomly assigned to gabapentin 300 mg after each haemodialysis session and pregabalin 75 mg daily. After 6 weeks of treatment, cross-over was performed and patients received the other drug for another 6 weeks. Short Form of McGill Pain Questionnaire and Visual Analogue Scale were used to evaluate pain and pruritus, respectively. At each week's visit, patients were interrogated in terms of adverse effects of study drugs. Baseline laboratory data and demographic characteristics were recorded from patient charts. Results: Forty (12 males, 28 females) out of 50 patients completed the study. Mean age was 58.2 ± 13.7. Overall, 29 out of 40 patients (72.5%) had pruritus symptoms at baseline evaluation. Fifteen patients (37.5%) were diabetic. Thirty-one out of 40 patients (77.5%) had electromyography (EMG)-proven peripheral neuropathy. Twenty three patients (57.5%) had both EMG-proven neuropathy and pruritus. Gabapentin and pregabalin improved both neuropathic pain and pruritus significantly. There was no difference between the study drugs in terms of efficacy against pain and pruritus. Conclusion: Treatment of neuropathic pain with either pregabalin or gabapentin effectively ameliorates uraemic itch. This paper examines the complex relationship betwen peripheral neuropathy and itch in patients receiving haemodialysis and considers whether treatment with gabapentin or pregabalin provides effective therapy. Either treatment was useful for modification of both pruritus and neuropathic pain. Further trials are required to explore this in greater detail.

Original languageEnglish
Pages (from-to)710-717
Number of pages8
JournalNephrology
Volume17
Issue number8
DOIs
Publication statusPublished - Jan 1 2012
Externally publishedYes

Fingerprint

Pruritus
Cross-Over Studies
Renal Dialysis
Maintenance
Prospective Studies
Neuralgia
Therapeutics
Peripheral Nervous System Diseases
Electromyography
gabapentin
Pregabalin
Pharmaceutical Preparations
Pain
Pain Measurement
Visual Analog Scale
Dialysis

Keywords

  • gabapentin
  • haemodialysis
  • itch
  • peripheral neuropathy
  • pregabalin
  • pruritus

ASJC Scopus subject areas

  • Nephrology

Cite this

Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients : A prospective, crossover study. / Solak, Yalcin; Biyik, Zeynep; Atalay, Huseyin; Gaipov, Abduzhappar; Guney, Figen; Turk, Suleyman; Covic, Adrian; Goldsmith, David; Kanbay, Mehmet.

In: Nephrology, Vol. 17, No. 8, 01.01.2012, p. 710-717.

Research output: Contribution to journalArticle

Solak, Yalcin ; Biyik, Zeynep ; Atalay, Huseyin ; Gaipov, Abduzhappar ; Guney, Figen ; Turk, Suleyman ; Covic, Adrian ; Goldsmith, David ; Kanbay, Mehmet. / Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients : A prospective, crossover study. In: Nephrology. 2012 ; Vol. 17, No. 8. pp. 710-717.
@article{7aa63c9777e14733bb1a49918a436cd7,
title = "Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: A prospective, crossover study",
abstract = "Aim: Pruritus is common in dialysis patients. Peripheral neuropathy is also prevalent in this patient population. However, the role of neuropathy in the genesis of uraemic itch has not been adequately studied to date. Therefore, we aimed to investigate the effects of gabapentin and pregabalin on uraemic pruritus along with neuropathic pain in patients receiving haemodialysis. Methods: This is a 14 week long randomized, prospective, cross-over trial. Haemodialysis patients with established neuropathy and/or neuropathic pain were included. Fifty patients were randomly assigned to gabapentin 300 mg after each haemodialysis session and pregabalin 75 mg daily. After 6 weeks of treatment, cross-over was performed and patients received the other drug for another 6 weeks. Short Form of McGill Pain Questionnaire and Visual Analogue Scale were used to evaluate pain and pruritus, respectively. At each week's visit, patients were interrogated in terms of adverse effects of study drugs. Baseline laboratory data and demographic characteristics were recorded from patient charts. Results: Forty (12 males, 28 females) out of 50 patients completed the study. Mean age was 58.2 ± 13.7. Overall, 29 out of 40 patients (72.5{\%}) had pruritus symptoms at baseline evaluation. Fifteen patients (37.5{\%}) were diabetic. Thirty-one out of 40 patients (77.5{\%}) had electromyography (EMG)-proven peripheral neuropathy. Twenty three patients (57.5{\%}) had both EMG-proven neuropathy and pruritus. Gabapentin and pregabalin improved both neuropathic pain and pruritus significantly. There was no difference between the study drugs in terms of efficacy against pain and pruritus. Conclusion: Treatment of neuropathic pain with either pregabalin or gabapentin effectively ameliorates uraemic itch. This paper examines the complex relationship betwen peripheral neuropathy and itch in patients receiving haemodialysis and considers whether treatment with gabapentin or pregabalin provides effective therapy. Either treatment was useful for modification of both pruritus and neuropathic pain. Further trials are required to explore this in greater detail.",
keywords = "gabapentin, haemodialysis, itch, peripheral neuropathy, pregabalin, pruritus",
author = "Yalcin Solak and Zeynep Biyik and Huseyin Atalay and Abduzhappar Gaipov and Figen Guney and Suleyman Turk and Adrian Covic and David Goldsmith and Mehmet Kanbay",
year = "2012",
month = "1",
day = "1",
doi = "10.1111/j.1440-1797.2012.01655.x",
language = "English",
volume = "17",
pages = "710--717",
journal = "Nephrology",
issn = "1320-5358",
publisher = "Wiley Blackwell",
number = "8",

}

TY - JOUR

T1 - Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients

T2 - A prospective, crossover study

AU - Solak, Yalcin

AU - Biyik, Zeynep

AU - Atalay, Huseyin

AU - Gaipov, Abduzhappar

AU - Guney, Figen

AU - Turk, Suleyman

AU - Covic, Adrian

AU - Goldsmith, David

AU - Kanbay, Mehmet

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Aim: Pruritus is common in dialysis patients. Peripheral neuropathy is also prevalent in this patient population. However, the role of neuropathy in the genesis of uraemic itch has not been adequately studied to date. Therefore, we aimed to investigate the effects of gabapentin and pregabalin on uraemic pruritus along with neuropathic pain in patients receiving haemodialysis. Methods: This is a 14 week long randomized, prospective, cross-over trial. Haemodialysis patients with established neuropathy and/or neuropathic pain were included. Fifty patients were randomly assigned to gabapentin 300 mg after each haemodialysis session and pregabalin 75 mg daily. After 6 weeks of treatment, cross-over was performed and patients received the other drug for another 6 weeks. Short Form of McGill Pain Questionnaire and Visual Analogue Scale were used to evaluate pain and pruritus, respectively. At each week's visit, patients were interrogated in terms of adverse effects of study drugs. Baseline laboratory data and demographic characteristics were recorded from patient charts. Results: Forty (12 males, 28 females) out of 50 patients completed the study. Mean age was 58.2 ± 13.7. Overall, 29 out of 40 patients (72.5%) had pruritus symptoms at baseline evaluation. Fifteen patients (37.5%) were diabetic. Thirty-one out of 40 patients (77.5%) had electromyography (EMG)-proven peripheral neuropathy. Twenty three patients (57.5%) had both EMG-proven neuropathy and pruritus. Gabapentin and pregabalin improved both neuropathic pain and pruritus significantly. There was no difference between the study drugs in terms of efficacy against pain and pruritus. Conclusion: Treatment of neuropathic pain with either pregabalin or gabapentin effectively ameliorates uraemic itch. This paper examines the complex relationship betwen peripheral neuropathy and itch in patients receiving haemodialysis and considers whether treatment with gabapentin or pregabalin provides effective therapy. Either treatment was useful for modification of both pruritus and neuropathic pain. Further trials are required to explore this in greater detail.

AB - Aim: Pruritus is common in dialysis patients. Peripheral neuropathy is also prevalent in this patient population. However, the role of neuropathy in the genesis of uraemic itch has not been adequately studied to date. Therefore, we aimed to investigate the effects of gabapentin and pregabalin on uraemic pruritus along with neuropathic pain in patients receiving haemodialysis. Methods: This is a 14 week long randomized, prospective, cross-over trial. Haemodialysis patients with established neuropathy and/or neuropathic pain were included. Fifty patients were randomly assigned to gabapentin 300 mg after each haemodialysis session and pregabalin 75 mg daily. After 6 weeks of treatment, cross-over was performed and patients received the other drug for another 6 weeks. Short Form of McGill Pain Questionnaire and Visual Analogue Scale were used to evaluate pain and pruritus, respectively. At each week's visit, patients were interrogated in terms of adverse effects of study drugs. Baseline laboratory data and demographic characteristics were recorded from patient charts. Results: Forty (12 males, 28 females) out of 50 patients completed the study. Mean age was 58.2 ± 13.7. Overall, 29 out of 40 patients (72.5%) had pruritus symptoms at baseline evaluation. Fifteen patients (37.5%) were diabetic. Thirty-one out of 40 patients (77.5%) had electromyography (EMG)-proven peripheral neuropathy. Twenty three patients (57.5%) had both EMG-proven neuropathy and pruritus. Gabapentin and pregabalin improved both neuropathic pain and pruritus significantly. There was no difference between the study drugs in terms of efficacy against pain and pruritus. Conclusion: Treatment of neuropathic pain with either pregabalin or gabapentin effectively ameliorates uraemic itch. This paper examines the complex relationship betwen peripheral neuropathy and itch in patients receiving haemodialysis and considers whether treatment with gabapentin or pregabalin provides effective therapy. Either treatment was useful for modification of both pruritus and neuropathic pain. Further trials are required to explore this in greater detail.

KW - gabapentin

KW - haemodialysis

KW - itch

KW - peripheral neuropathy

KW - pregabalin

KW - pruritus

UR - http://www.scopus.com/inward/record.url?scp=84868160098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868160098&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1797.2012.01655.x

DO - 10.1111/j.1440-1797.2012.01655.x

M3 - Article

VL - 17

SP - 710

EP - 717

JO - Nephrology

JF - Nephrology

SN - 1320-5358

IS - 8

ER -